会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明申请
    • Methods of Treating Kawasaki Disease using IL-1beta Antibodies
    • 使用IL-1beta抗体治疗川崎病的方法
    • US20160002328A1
    • 2016-01-07
    • US14861191
    • 2015-09-22
    • Hermann GramThomas Jung
    • Hermann GramThomas Jung
    • C07K16/24
    • C07K16/245A61K39/3955A61K2039/505C07K2317/21C07K2317/565C07K2317/76C07K2317/92
    • This invention relates to a novel use of IL-1β-ligand/IL-1 receptor disrupting compounds (herein referred to as “IL-1beta Compounds”); such as small molecular compounds disrupting IL-1b ligand-IL-1 receptor interaction, IL-1b antibodies or IL-1 receptor antibodies, e.g. IL-1b binding molecules described herein, e.g. antibodies disclosed herein, e.g. IL-1b binding compounds or IL-1 receptor binding compounds, and/or RNA compounds decreasing either IL-1b ligands or IL-1 receptor protein levels, in the treatment and/or prevention of auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome and to methods of treating and/or preventing auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome, in mammals, particularly humans.
    • 本发明涉及IL-1和bIG - 配体/ IL-1受体破坏化合物(本文中称为“IL-1β化合物”)的新用途。 例如破坏IL-1b配体-IL-1受体相互作用的小分子化合物,IL-1b抗体或IL-1受体抗体。 本文所述的IL-1b结合分子,例如 本文公开的抗体,例如 IL-1b结合化合物或IL-1受体结合化合物,和/或降低IL-1b配体或IL-1受体蛋白水平的RNA化合物,用于治疗和/或预防自身炎症综合征。 少年类风湿性关节炎或成人类风湿性关节炎综合征以及治疗和/或预防自身炎症综合征的方法,例如, 少年类风湿关节炎或成人类风湿关节炎综合征,在哺乳动物,特别是人类。
    • 3. 发明申请
    • Methods of Using IL-1beta Compounds
    • 使用IL-1β化合物的方法
    • US20150322148A1
    • 2015-11-12
    • US14810556
    • 2015-07-28
    • Philip LoweHermann GramThomas JungTimothy WrightTrevor Mundel
    • Philip LoweHermann GramThomas JungTimothy WrightTrevor Mundel
    • C07K16/24
    • C07K16/245A61K39/3955A61K2039/505C07K2317/21C07K2317/56C07K2317/565C07K2317/76C07K2317/92
    • This invention relates to methods employing IL-1β-ligand/IL-1 receptor disrupting compounds (herein referred to as “IL-1beta Compounds”); such as small molecular compounds disrupting IL-1β ligand-IL-1 receptor interaction, IL-1β antibodies or IL-1 receptor antibodies, e.g. IL-1β binding molecules as described herein, e.g. antibodies disclosed herein, e.g. IL-1β binding compounds or IL-1 receptor binding compounds, and/or RNA compounds decreasing either IL-1β ligands or IL-1 receptor protein levels, in the treatment and/or prevention of auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome and to methods of treating and/or preventing auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome, in mammals, particularly humans.
    • 本发明涉及使用IL-1和配体/ IL-1受体破坏性化合物(本文中称为“IL-1β化合物”)的方法; 例如破坏IL-1和bgr的小分子化合物; 配体-IL-1受体相互作用,IL-1和bgr; 抗体或IL-1受体抗体。 IL-1和bgr 如本文所述的结合分子。 本文公开的抗体,例如 IL-1和bgr 结合化合物或IL-1受体结合化合物,和/或降低IL-1和bgr的RNA化合物; 配体或IL-1受体蛋白水平,用于治疗和/或预防自身炎症综合征,例如, 少年类风湿性关节炎或成人类风湿性关节炎综合征以及治疗和/或预防自身炎症综合征的方法,例如, 少年类风湿关节炎或成人类风湿关节炎综合征,哺乳动物,特别是人类。
    • 5. 发明申请
    • Novel Use of IL-1beta Compounds
    • IL-1β化合物的新用途
    • US20120039910A1
    • 2012-02-16
    • US13283165
    • 2011-10-27
    • Phil LoweHermann GramThomas JungTimothy WrightTrevor Mundel
    • Phil LoweHermann GramThomas JungTimothy WrightTrevor Mundel
    • A61K39/395A61P37/02
    • C07K16/245A61K39/3955A61K2039/505C07K2317/21C07K2317/56C07K2317/565C07K2317/76C07K2317/92
    • This invention relates to methods employing IL-1β-ligand/IL-1 receptor disrupting compounds (herein referred to as “IL-1beta Compounds”); such as small molecular compounds disrupting IL-1β ligand-IL-1 receptor interaction, IL-1β antibodies or IL-1 receptor antibodies, e.g. IL-1β binding molecules as described herein, e.g. antibodies disclosed herein, e.g. IL-1β binding compounds or IL-1 receptor binding compounds, and/or RNA compounds decreasing either IL-1β ligands or IL-1 receptor protein levels, in the treatment and/or prevention of auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome and to methods of treating and/or preventing auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome, in mammals, particularly humans.
    • 本发明涉及使用IL-1和配体/ IL-1受体破坏性化合物(本文中称为“IL-1β化合物”)的方法; 例如破坏IL-1和bgr的小分子化合物; 配体-IL-1受体相互作用,IL-1和bgr; 抗体或IL-1受体抗体。 IL-1和bgr 如本文所述的结合分子。 本文公开的抗体,例如 IL-1和bgr 结合化合物或IL-1受体结合化合物,和/或降低IL-1和bgr的RNA化合物; 配体或IL-1受体蛋白水平,用于治疗和/或预防自身炎症综合征,例如, 少年类风湿性关节炎或成人类风湿性关节炎综合征以及治疗和/或预防自身炎症综合征的方法,例如, 少年类风湿关节炎或成人类风湿关节炎综合征,在哺乳动物,特别是人类。
    • 10. 发明授权
    • Vehicle seat
    • 车座
    • US08820790B2
    • 2014-09-02
    • US13879338
    • 2011-10-05
    • Frank WenzSasa GalijasevicThomas Jung
    • Frank WenzSasa GalijasevicThomas Jung
    • B60R22/26
    • B60N2/58B60N2/688B60R22/26B60R2022/1818B60R2022/1837
    • A vehicle seat includes a sitting part structure and a seatback structure which is arranged so as to pivot at its lower end on the sitting part structure and is covered by a seatback cover and to which, in its upper region on the vehicle sill side, is secured a belt deflector. The belt deflector has a belt runner opening for a seatbelt, which faces in the longitudinal direction of the vehicle. The seatbelt is guided out of an automatic belt roller mechanism, which accommodates one end of the seatbelt, through the belt runner opening in the belt deflector. The belt deflector is covered by the seatback cover which has a belt-passage through-opening which coincides with the belt runner opening and is covered on the front face of the seatback by a belt cover which has a belt-guide slot and is connected to the seatback cover.
    • 车辆座椅包括座位结构和座椅靠背结构,其被布置成在其下端枢转在座椅构件上并被座椅靠背罩覆盖,并且在其车槛侧的上部区域中 固定皮带导流板。 皮带偏转器具有面向车辆纵向方向的安全带的皮带轮开口。 安全带从通过皮带导流板中的皮带轮开口的自动皮带辊机构引导出,该机构容纳安全带的一端。 带偏转器被座椅靠背罩覆盖,该座椅靠背罩具有与皮带导流口开口重合的带通道通孔,并且通过带罩覆盖在座椅靠背的前表面上,带盖具有皮带导向槽并连接到 座椅靠背罩。